

---

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER  
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER  
THE SECURITIES EXCHANGE ACT OF 1934

For the month of January 2024

Commission File Number: 001-41598

**YS BIOPHARMA CO., LTD.**  
(Exact name of registrant as specified in its charter)

**Building No. 2, 38 Yongda Road**  
**Daxing Biomedical Industry Park**  
**Daxing District, Beijing, PRC**  
**Tel: 010-89202086**  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F  Form 40-F

---

---

EXHIBITS

**Exhibit No.**   **Description**

---

99.1   [Press Release](#)

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**YS Biopharma Co., Ltd.**

Date: January 8, 2024

By: /s/ Hui Shao

Name: Hui Shao

Title: Director and Chief Executive Officer

**YS Biopharma Announces Changes to its Board Committees**

GAITHERSBURG, Md., January 8, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ: YS) (“YS Biopharma” or the “Company”), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that the Company’s Board of Directors (the “Board”) has approved Ms. Rui Yu as the new Chairperson of its Audit Committee, as a member of its Compensation Committee, and as a member of the Nominating and Corporate Governance Committee on January 7, 2024 (Beijing Time), with immediate effect. Ms. Yu currently serves as a partner at Oceanpine Capital, a position she has held since 2021. Prior to that, she served as a managing director at China Renaissance Group and vice president and head of China healthcare research at Gerson Lehman Group. Ms. Yu received her Bachelor of Science degree from Guangdong Pharmaceutical University, her Master of Science degree from the University of Missouri School of Medicine, and her MBA from the University of Chicago Booth School of Business with concentrations in finance, accounting and entrepreneurship.

Accordingly, the membership of each Board Committee will be as follows:

***Audit Committee***

Rui Yu (Chairperson), Viren Mehta, and Shaojing Tong

***Compensation Committee***

Viren Mehta (Chairperson), Ajit Shetty, Shaojing Tong, and Rui Yu

***Nominating and Corporate Governance Committee***

Ajit Shetty (Chairperson), Viren Mehta, Rui Yu, and Yi Zhang

**About YS Biopharma**

YS Biopharma is a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and commercializing new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA® immunomodulating technology platform and a series of preventive and therapeutic biologics with a potential for improved Rabies, Coronavirus, Hepatitis B, Influenza, and Shingles vaccines.

YS Biopharma operates in China, the United States, Singapore and the Philippines, and is led by a management team that combines rich local expertise and global experience in the bio-pharmaceutical industry. For more information, please visit [investor.ysbiopharm.com](http://investor.ysbiopharm.com).

**Investor Relations Contacts**

Robin Yang

Partner, ICR, LLC

Tel: +1 (212) 537-4035

Email: [YSBiopharma.IR@icrinc.com](mailto:YSBiopharma.IR@icrinc.com)